Methods are disclosed for increasing ribozyme catalytic activity without reducing specificity, which methods comprise contacting an RNA molecule with a ribozyme and a 2'-O-substituted facilitator oligonucleotide. The present invention further provides compositions comprising a ribozyme and an effective amount of a 2'-O-methyl substituted facilitator oligonucleotide. The use of a facilitator, particularly a 2'-O-substituted facilitator, and more especially a 2'-O-methyl substituted facilitator, greatly enhances ribozyme catalytic activity, frequently making an otherwise inactive ribozyme active.
|
1. A method for increasing the catalytic activity of a ribozyme comprising contacting a target RNA molecule with the ribozyme and a 2'-O-substituted facilitator oligonucleotide.
2. A method according to
3. A method according to
4. The method according to
5. The method according to
6. A method according to
7. A method according to
8. A method according to
9. A method according to
10. A method according to
11. A method according to
12. A method according to
13. A method according to
14. A method according to
16. A composition according to
17. A composition according to
18. The composition according to
19. The composition according to
20. A composition according to
21. A composition according to
|
|||||||||||||||||||||||||||||||||||||||||
This application is a continuation-in-part of application Ser. No. 08/431,625, filed May 1, 1995, and now U.S. Pat. No. 5,612,469, issued Mar. 18, 1997; which is a continuation of application Ser. No. 08/138,896, filed Oct. 19, 1993, now abandoned; which is a continuation of application Ser. No. 07/830,713, filed Feb. 4, 1992, now abandoned.
1. Field of the Invention
This invention relates to ribozymes that cleave RNA, and more specifically to the enhancement of ribozyme catalytic activity using facilitator oligonucleotides complementary to an RNA sequence contiguous to the ribozyme.
2. Description of the Related Art
Catalytic RNA, or "ribozymes" consist of a catalytic core having flanking sequences adjacent to the core that hybridize to the substrate RNA. The simplest catalytic core is an RNA motif known as a hammerhead. Since the discovery of RNA catalysts (ribozymes) by Cech, there has been a desire to design ribozymes to cleave viral or messenger RNA with high specificity and at a rapid rate. Historically, these requirements have been mutually limiting.
Ribozyme specificity depends on the number of base pairs formed between the ribozyme flanking sequences and its RNA substrate. Goodchild and Kohli studied the cleavage of a sequence from HIV-1 RNA by various hammerhead ribozymes. Increased base pairing has been shown to decrease the rate of cleavage. Goodchild and Kohli, Arch. Biochem. Biophys. 284, 386 (1991). They found that shorter flanking sequences resulted in weaker binding between the ribozyme and the cleavage products together with increased rate of cleavage. A ribozyme with 12 base flanking sequences cleaved 10 times faster then one with 20 bases.
However, to have the requisite selectivity or specificity, i.e., the ability to discriminate among all RNA molecules in a cell, a ribozyme must form a minimum of about 15 base pairs with the target substrate. This requirement for selectivity limits the rate of cleavage that may be realized.
Accordingly, ribozymes having increased catalytic activity or methods of increasing ribozyme catalytic activity are needed.
The present invention provides methods for increasing ribozyme catalytic activity without reducing specificity, which methods comprise contacting a target RNA molecule with a ribozyme and a facilitator oligonucleotide. The present invention further provides compositions comprising a ribozyme and an effective amount of a facilitator oligonucleotide.
The facilitators according to the invention comprise a nucleotide sequence of from 5 to 50 nucleotides complementary to a sequence of ribonucleotides in the target RNA adjacent to the sequence to which the ribozyme's flanking sequence is complementary. The facilitator can be RNA, DNA, or a combination thereof. From one to all facilitator ribonucleotides can be modified in the same or different way at the base, sugar, or intemucleoside linkage and in any manner such that the modification(s) does not prevent hybridization to the target under physiological conditions. A preferred modification is at the 2'-O position of one or more facilitator nucleotides. Particularly preferred are 2'-O-methyl substituents.
The combination of facilitator oligonucleotide and ribozyme according to the invention has an increased rate of substrate cleavage relative to that of the ribozyme alone.
The foregoing merely summarizes certain aspects of the present invention and is not intended, nor should it be construed, as limiting the invention in a manner. All patents and other publications are hereby incorporated by reference in their entirety.
FIG. 1 shows the nucleotide sequences of substrate RNA (S) SEQ ID NO:1, ribozyme (R) SEQ ID NO:2 and facilitator oligodeoxynucleotides F1 SEQ ID NO:3, F2 SEQ ID NO:4, F3 SEQ ID NO:5, and facilitator ribooligonucleotide F4 with the same sequence as F1. The site of cleavage of substrate is indicated by the arrow.
FIG. 2A is an autoradiograph showing the results of cleavage of radiolabeled substrate S by ribozyme R without facilitator oligonucleotide to give products P1 and P2 containing 20 and 13 nucleotides respectively.
FIG. 2B is an autoradiograph showing the results of cleavage of radiolabeled substrate S by ribozyme R in the presence of facilitator oligonucleotide F1 to give products P1 and P2 containing 20 and 13 nucleotides respectively.
FIG. 3 is a graph of the time courses of cleavage reactions using facilitator oligonucleotides F1, F2, and F3 and a control reaction with no facilitator oligonucleotide.
FIG. 4 is a bar graph showing the enhancement of cleavage in the presence of both modified and unmodified facilitators according to the invention and described in Example 4.
FIG. 5 is a time-course graph demonstrating the influence of facilitator F2 on the kinetics of cleavage by ribozyme R2 of substrate S1 as described in Example 5.
FIG. 6 is a time-course graph showing the influence of facilitator F2 on the kinetics of cleavage by ribozyme R17 of substrate S1 as described in Example 5.
FIG. 7 shows time courses for cleavage of a substrate by three related ribozymes with progressively longer flanking sequences; R(4+4), R(5+5), and R(6+6), in the presence and absence of facilitator, as described in Example 6.
FIG. 8 is a bar graph representation of the cleavage of a substrate RNA by a modified ribozyme in the presence and absence of a modified facilitator.
The development of antiviral drugs based on RNA catalysts has been inhibited by the mutually limiting requirements of high specificity and RNA cleavage rate. Increased base pairing between a ribozyme and a substrate RNA has been shown to decrease the rate of RNA cleavage. In order for a ribozyme to discriminate between all RNAs in a cell, a ribozyme must form about 15 base pairs with the target. However, longer flanking sequences in ribozymes is related to decreased catalytic cleavage.
It has been unexpectedly discovered that the rate of cleavage of substrate RNA by a ribozyme is enhanced by introducing an oligonucleotide into the system that hybridizes immediately adjacent to the ribozyme.
The facilitator oligonucleotides are preferably synthesized to comprise from one to all modified nuclcotides, which can be ribonucleotides, deoxyribonucleotides, or a combination thereof. The modifications can be to the base, sugar, and/or internucleoside linkage moieties, the only limitation being that the modification or modifications do not preclude target hybridization under physiological conditions. Preferably, the modifications are such that they confer nuclease resistance upon the facilitator, increase the rate of ribozyme cleavage, and/or increase facilitator cellular uptake. Nuclease resistance is desirable, of course, to extend the facilitators half-life in vivo and thereby increase its efficacy.
Many nucleotide modifications are known in the art and are suitable for use with facilitators of the instant invention. Such modifications include, but are not limited to, those to the intemucleoside linkage. Thus, one or more phosphodiester linkages of the facilitator oligonucleotide can be substituted by, for example, a phosphoramidate, phosphotriester phosphorothioate, phosphorodithioate, alkylphosphonate (especially methylphosphonate), arylphosphonate, alkylphosphonothioate (especially methylphosphonothioate), or arylphosphonothioate internucleoside linkage.
Other modifications include those to the sugar moiety, particularly at the 2' position. Such modification include, but are not limited to, incorporation of 2'-O-alkyl, especially 2'-O-methyl, 2'-O-aryl, and 2'-O-alkoxyalkyl, such as 2'-O-methoxymethyl and 2'-O-ethoxymethyl.
In a preferred embodiment, from one to all of the facilitator's sugar residues are modified at the 2' position. Preferably, the modification is a 2'-O-methyl substituent. Preferably, at least 20%, more preferably at least 50%, and most preferably all of the facilitator's sugar residues are 2'-O-methylated.
Facilitator oligonucleotides according to the invention can be selected to bind to a sequence contiguous to the flanking sequence at either the 5' or the 3' side of the ribozyme. In addition, a combination of two facilitator oligonucleotides may be employed, where one facilitator is bound contiguously to the 3' flanking sequence and the other to the 5' flanking sequence. Alternatively, a plurality of facilitators may be employed to catalyze ribozyme activity. For example, in a system employing three facilitators, two facilitators could bind contiguously to the 3' flanking sequence, while a single additional facilitator could bind contiguously to the 5' flanking sequence. The skilled artisan will recognize that a variety of other combinations are possible and are contemplated as within the scope of the instant invention.
The facilitator oligonucleotides of the present invention typically comprise between about 5 and 50 nucleotides. More preferred facilitator oligonucleotides comprise between about 5 and 15 nucleotides. Particularly preferred facilitators according to the invention comprise about 10-15 nucleotides. Selection of a facilitator of a specific length is related to the length of the ribozyme flanking sequences. It is routine matter following the teachings disclosed herein for one of ordinary skill in the art to determine both suitable and optimal lengths of facilitators.
In addition, facilitator oligonucleotides may be selected to have between about 5 and 50 nucleotides complementary to the RNA substrate sequence as well as additional nucleotides that are not complementary to the RNA.
Facilitator oligonucleotides are synthesized to bind to the desired RNA sequences such that they are contiguous to the flanking sequences of various ribozymes that cleave related RNA sequences. Facilitator oligonucleotides can be synthesized using standard techniques.
The facilitator oligonucleotides may also be synthesized such that they are not completely contiguous to the flanking sequence of the desired ribozyme. For example, the facilitator may be synthesized such that, when the ribozyme and facilitator oligonucleotide are bound to the substrate RNA, a small gap of from one to about five oligonucleotides exists between the ribozyme and the facilitator oligonucleotide.
By increasing the number of bases of the substrate RNA bound near the cleavage site, facilitators permit use of faster acting ribozymes with shorter flanking sequences. In viral applications, facilitators have dual benefit in also directing cleavage of the viral RNA by endogenous ribonuclease H. Furthermore, recent studies suggest that facilitators are especially efficient effectors for enhancing ribozyme mediate cleavage of long substrates (Jankowski and Schwenzer, Biochemistry 35, 15313 (1996)), and have been shown to be of potential use in gene therapy for the treatment of Hepatitis C virus infection (Welch ct al., Gene Therapy 3, 994 (1996)).
The present invention also includes compositions that comprise a ribozyme and an effective amount of a facilitator oligonucleotide as described above. Such composition are useful for both in vitro and in vivo purposes. In vitro, the combination of ribozyme and facilitator oligonucleotide are useful for selective modulation of gene expression to determine, for example, the role of the gene in cellular processes. Gene expression can be inhibited by the combination of a ribozyme and facilitator targeted to mRNA transcription product of the gene or that of a promoter. Alternatively, gene expression can be enhanced by targeting the mRNA transcription product of a repressor gene.
The compositions of the invention may be administered parenterally, orally, by inhalation or spray or rectally in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles. The terms "parenteral" as used herein includes subcutaneous injections, intravenous, intramuscular, intrastemal injection or infusion techniques. The compositions of the invention would be provided in a pharmaceutical formulation comprising the composition and a pharmaceutically acceptable carrier. In order for the compositions to be suitable for oral administration, oligonucleotides and ribozymes must be resistant to nucleases. Such resistance to nucleases may be imparted to the oligonucleotides and ribozymes by, for example, internucleotide phosphate modifications, as discussed previously.
The amount of active composition that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. It will be understood that the specific dose level must be empirically determined based on a number of factors including the activity of the specific composition employed, the age, body weight, general health, sex, diet, time of administration, route of administration, and severity of the particular disease undergoing therapy. In any treatment, however, the compositions comprising the ribozyme and facilitator oligonucleotide must be administered to individuals in a manner capable of delivering the oligonucleotide and ribozyme initially into the blood stream and subsequently into cells.
One skilled in the art will recognize that modifications may be made in the present invention without deviating from the spirit or scope of the invention. The invention is illustrated further by the following examples, which are not be construed as limiting the invention or scope of the specific procedures described herein.
PAC Example 1Nucleic Acid Preparation
1. Preparation of RNA Substrate
A synthetic RNA substrate strand (S) was prepared to correspond to the sequence 146-173 in HIV-1 RNA. This RNA substrate was transcribed from synthetic DNA templates following a method described by Milligan and Uhlenbeck, Nucleic Acids Res. 15 8783-8798 (1987), in a reaction containing Tris·HCl (40 mM, pH 8.1), MgCl2 (6 mM), spermidine (1 mM), dithiothreitol (50 mM), bovine serum albumin (50 μg per ml), inorganic pyrophosphatase (4 units per ml), T7 RNA polymerase (4000 units per ml) and four ribonucleotide 5'-triphosphates (1μM each) supplemented with a-32 P-UTP (3000 Ci/mmol). After incubation at 37°C for 2 hours, the RNA was purified by electrophoresis in 10% polyacrylamide gels containing 8 M urea. The radiolabeled RNA was quantitated using the specific activity of the incorporated 32 P.
2. Preparation of Hammerhead Ribozyme
A hammerhead ribozyme (R) designed to cleave RNA substrate strand S was prepared. The hammerhead ribozyme was prepared by automated chemical synthesis using standard phosphoramidite reagents. Products were purified by electrophoresis in 15% polyacrylamide gels containing 8 M urea, eluted by crush and soak in 0.5 M ammonium acetate, desalted and quantitated by UV absorption.
3. Preparation of Facilitator and Control Oligonucleotides
Facilitator oligodeoxyribonucleotides F1, F2, and F3 were prepared to contain 13, 10, and 6 nucleotides respectively, and to hybridize to substrate S contiguously with ribozyme R. Facilitator oligoribonucleotide F4 was prepared with the same sequence as F1 except that each T was replaced with a U. In addition, a control oligonucleotide having a random sequence was synthesized. The sequences of the facilitator oligonucleotides are shown in FIG. 1.
Both ribo- and deoxyriboligonucleotides were prepared by automated chemical synthesis utilizing essentially the same procedures set forth in part 2 of this Example.
Cleavage of Substrate RNA
The cleavage of substrate RNA by ribozyme R was studied both with and without facilitator oligonucleotide F1. The chain lengths expected from cleavage at the site are indicated in FIG. 1.
The cleavage reactions were run as follows: a solution (45 μl) containing substrate (13.4 μM), ribozyme (0.67 μM) and facilitator where appropriate (20 μM) in to mM Tris·HCl (pH 7.4) was brought to 37°C Reaction was initiated by the addition of MgCl2 (5 μL, 200 mM). After times of 0.5, 1, 2, 5, and 10 minutes, aliquots of 5 μl of saturated urea:200 mM EDTA (1:1) and cooled to about -70°C with dry ice to stop the reaction. The samples were then denatured by heating in formamide loading buffer at 90°C for 3 minutes and subsequently analyzed alongside molecular weight markers by electrophoresis in 15% polyacrylamide gel containing 7M urea. The products were autoradiographed. The autoradiographs are shown in FIG. 2. Panel A shows the results of the cleavage reaction without any facilitator oligonucleotide and Panel B shows the results of cleavage with facilitator oligonucleotide F1. These results demonstrate the enhancement of ribozyme cleavage of a substrate RNA by facilitator oligonucleotides.
Relation of Facilitator Length to Ribozyme Activity
Cleavage of substrate RNA by ribozyme R was determined in the presence of facilitator oligonucleotides (F1, F2, F3, and F4) of varying length. Cleavage reactions were run under conditions substantially similar to those employed in Example 2 above. Products and starting materials were quantitated for each time point. Autoradiograph gels were sliced and the materials on the slices quantitated y scintillation counting. The results of this experiment are graphically shown in FIG. 3.
Cleavage with no facilitator reached about 94% completion after about 160 minutes. The facilitator of 13 deoxynucleotides significantly reduced reaction half life. Table 1 shows the time required for ribozyme to cleave 10 equivalents of substrate at 37°C The longest facilitator, F1, reduced this half life time from 10 minutes to 1.3 minutes. The effects of facilitators F1 -F3 were inversely related to their lengths. A control oligonucleotide of the same length as F1 had no effect on the rate.
| TABLE 1 |
| ______________________________________ |
| Half-Lives of Substrate in the Presence |
| of Ribozyme and Facilitators |
| Facilitator [S]01 |
| Half-Life (min) |
| ______________________________________ |
| none 2.7 10 |
| F1 2.7 1.3 |
| F2 2.7 1.9 |
| F3 2.7 6.9 |
| none 0.9 40 |
| F1 0.9 4.9 |
| F4 0.9 12.3 |
| ______________________________________ |
| 1 Starting concentrations of substrate (μM) |
Effect of Chain Length and Backbone Modifications on Facilitator Activity
A synthetic RNA substrate strand, S2, comprising 36 ribonucleotides was prepared by automated chemical synthesis as described in earlier examples and labeled at the 5'-end with 32 p using polynucleotide kinase.
A hammerhead ribozyme, R1, comprising 35 ribonucleotides and four families of facilitator oligonucleotides designed to cleave the RNA substrate strand, S2, were prepared by automated chemical synthesis using standard phosphoramidite reagents.
The 4 families of facilitators were designed to hybridize to a sequence in the target, S2, immediately adjacent to the sequence to which the ribozyme's 3' flanking sequence hybridizes. Facilitators F11-F14 comprised 10-13-mer, respectively, oligoribonucleotides. Facilitators F5-F10 comprised 8-13-mer, respectively, 2'-O-Me oligoribonucleotides. Facilitators F15-F17 comprised 12-14-mer, respectively, oligodeoxyribonucleotides (phosphodiesters). Facilitators F18-F20 comprised 14-16-mer, respectively, oligodeoxyribo-nucleotide phosphorothioates. Because the facilitators were all designed to hybridized to the same target sequence 3' to the target sequence of the ribozyme's 3' flanking sequence, the 5'-most sequence of all of the facilitators is the same (except in that the oligodeoxyribonucleotides contained thymidine in place of uridine).
Products were purified by electrophoresis in 15% polyacrylamide gels containing 8M urea, eluted by crush and soak in 0.5M ammonium acetate, desalted, and quantitated by UV absorption.
The cleavage reactions were run as described in Example 2. FIG. 4 is a bar graph representation of cleavage enhancement provided by these different facilitators. Ribozyme activity parallels the expected hybridization strength of the facilitator with respect both to length and modification. RNA and 2'-OMe forms are more potent than DNA/PO. The least potent is DNA/PS. Furthermore, below a certain chain length (11 nucleotides in the case of 2'O-Me and RNA), activity falls off with decreasing chain length.
Enhancement of Ribozyme Activity by 2'-O-Methylated Facilitators
The time course of cleavage of a 29-mer substrate RNA, S1, by two 29-mer ribozymes that differ only in the number of residues with 2'O-Me substitutions in the core, R2 and R17, was determined in the presence of a 2'-OMe facilitator 13-mer oligoribonucleotide, F2.
Cleavage reactions were run under conditions substantially similar to those employed in Example 2, above. Products and starting materials were quantitated for each time point. Autoradiograph gels were sliced and the materials on the slices quantitated by scintillation counting. The results of this experiment are graphically presented in FIGS. 5 and 6. In both cases, substrate cleavage was greatly enhanced by F2, especially for R2, the more heavily 2'-OMe-substituted ribozyme, which showed virtually no activity in the absence of the facilitator. These experiments demonstrate the utility of 2'-O-modified facilitator oligonucleotides in enhancing cleavage by modified ribozymes.
Effect of2'-O-Me Facilitators on the Catalytic Activity of Ribozymes with Different Length Flanking Sequences
Three ribozymes were synthesized to determine the affect of ribozyme flanking sequence length when used in conjunction with 2'-O-Me facilitators. The ribozymes were designed to target substrate S2, supra, and comprised 18-mer core sequences with 5' and 3' flanking sequences of 4 nucleotides, R(4+4), 5 nucleotides (R(5+5)), and 6 nucleotides (R(6+6)).
Facilitator F21-23 comprised 13-mer 2'-O-Me oligoribonucleotides designed to hybridize to a sequence in the target immediately adjacent to the sequence to which the 3'-flanking sequence of ribozyme R(4+4), R(5+5), and R(6+6), respectively, hybridizes.
FIG. 7 shows the time course of cleavage of substrate S2 with the three ribozymes R(4+4), R(5+5) and R(6+6). Cleavage reactions were performed as described in Example 2. Alone, these ribozymes cleave poorly if at all. In the presence of their respective 2'-OMe facilitator (denoted by "F" in FIG. 7), cleavage by R(6+6) and especially R(5+5) is improved greatly, thus demonstrating the utility of modified facilitator oligonucleotides for enhancement of cleavage by ribozymes with different length flanking sequences.
Addition of facilitator to R(4+4) resulted in no significant effect in this experiment. Previous experiments (data not shown) have shown a positive affect by a facilitator on the activity of a 4+4 ribozyme. The particular length of each of the ribozyme's flanking sequences will vary among applications. They can be the same or different lengths, but should be of such length that when combined with a facilitator according to the invention the ribozyme and facilitator bind to the target under physiological conditions.
Cleavage of VEGF mRNA
Full length VEGF mRNA was targeted with excess ribozyme RZ-733 (SEQ ID NO. 6. 5'-GGUGGUCUGAUGAGGCCGUUAGGCCGAAACAUGG-3') (a (6+6) ribozyme designed to cleave the VEGF RNA at position 733 from the 5' end) in rabbit reticulocyte cell lysate. Studies were conducted as described in Example 2 with a 2'-O-methylated 13-mer facilitator F24 (SEQ. ID NO. 7. 5'-TTAATCGGTCTTT-3'), which bound to the target adjacent to the 3' end of the ribozyme. The autoradiogram showed that cleavage was enhanced with the fully 2'-O-methylated facilitator.
Cleavage of a Full Length RNA by a Modified Ribozyme in the Presence and Absence of a Modified Facilitator Oligonucleotide
A modified 34-mer ribozyme, R3, was used to cleave full length HCV RNA in the presence and absence of a 2'-O-methylated 13-mer facilitator F25. The cleavage reaction was carried out as described in Example 2. FIG. 8 displays the results. The first row beneath the bar graph is "±F" with "+" meaning ribozyme plus facilitator and "-" meaning ribozyme without facilitator. The second row is "flanking sequence and indicates the type of modifications (if any) in the ribozyme flanking sequence ("PO"=phosphodiester intemucleoside linkages; "PS"=phosphorothioate intemucleotide linkages; "2'OMe/PO"=2'-O-methylated nucleotides with phosphodiester internucleoside linkages; and "2'OMe/PS"=2'-O-methylated nucleotides with phosphorothioate internucleoside linkages). The third row describes the modifications to the core U nucleotides (indicated by an "*"), being either "-" (no modification), "A" (A substituted for U), "Ups " (phosphorothioate intemucleoside linkage), and "2' OMe" (2'-O-methylated U). The fourth row indicates whether there was preincubation ("-"=no and "+"=yes). The facilitator was 2'-O-methylated and enhanced cleavage in each case.
The results demonstrate that a 2'-O-methyl modified facilitator oligonucleotide enhances cleavage of a substrate RNA by a modified ribozyme.
From the foregoing, it will appreciated that although specific embodiments of the invention have been described herein for purposes of illustration, various modifications may be made without deviating from the spirit or scope of the invention.
| __________________________________________________________________________ |
| # SEQUENCE LISTING |
| - <160> NUMBER OF SEQ ID NOS: 7 |
| - <210> SEQ ID NO 1 |
| <211> LENGTH: 33 |
| <212> TYPE: RNA |
| <213> ORGANISM: Unknown Organism |
| <220> FEATURE: |
| <223> OTHER INFORMATION: Description of Unknown Or - #ganism: nucleotide |
| sequence of substrate RNA |
| - <400> SEQUENCE: 1 |
| # 33 aguc aguguggaaa auc |
| - <210> SEQ ID NO 2 |
| <211> LENGTH: 35 |
| <212> TYPE: RNA |
| <213> ORGANISM: Artificial Sequence |
| <220> FEATURE: |
| #Sequence: nucleotideON: Description of Artificial |
| sequence of ribozyme |
| - <400> SEQUENCE: 2 |
| # 35 ccgu uaggccgaaa cuaaa |
| - <210> SEQ ID NO 3 |
| <211> LENGTH: 13 |
| <212> TYPE: DNA |
| <213> ORGANISM: Artificial Sequence |
| <220> FEATURE: |
| #Sequence: facilitatorN: Description of Artificial |
| oligodeoxynucleotide |
| - <400> SEQUENCE: 3 |
| # 13 |
| - <210> SEQ ID NO 4 |
| <211> LENGTH: 10 |
| <212> TYPE: DNA |
| <213> ORGANISM: Artificial Sequence |
| <220> FEATURE: |
| #Sequence: facilitatorN: Description of Artificial |
| oligodeoxynucleotide |
| - <400> SEQUENCE: 4 |
| # 10 |
| - <210> SEQ ID NO 5 |
| <211> LENGTH: 13 |
| <212> TYPE: RNA |
| <213> ORGANISM: Artificial Sequence |
| <220> FEATURE: |
| #Sequence: facilitatorN: Description of Artificial |
| oligonucleotide |
| - <400> SEQUENCE: 5 |
| # 13 |
| - <210> SEQ ID NO 6 |
| <211> LENGTH: 34 |
| <212> TYPE: RNA |
| <213> ORGANISM: Artificial Sequence |
| <220> FEATURE: |
| #Sequence:R INFORMATION: Description of Artificial |
| #RZ-733ligonucleotide sequence of ribozyme |
| - <400> SEQUENCE: 6 |
| # 34 cguu aggccgaaac augg |
| - <210> SEQ ID NO 7 |
| <211> LENGTH: 13 |
| <212> TYPE: DNA |
| <213> ORGANISM: Artificial Sequence |
| <220> FEATURE: |
| #Sequence: facilitatorN: Description of Artificial |
| oligonucleotide |
| - <400> SEQUENCE: 7 |
| # 13 |
| __________________________________________________________________________ |
| Patent | Priority | Assignee | Title |
| 10036025, | Feb 01 2002 | Life Technologies Corporation | Oligonucleotide compositions with enhanced efficiency |
| 10106793, | Feb 01 2002 | Life Technologies Corporation | Double-stranded oligonucleotides |
| 10196640, | Feb 01 2002 | Life Technologies Corporation | Oligonucleotide compositions with enhanced efficiency |
| 10626398, | Feb 01 2002 | Life Technologies Corporation | Oligonucleotide compositions with enhanced efficiency |
| 6683167, | Jul 23 1992 | University of Massachusetts Worcester | Hybrid oligonucleotide phosphorothioates |
| 7045609, | Jul 23 1992 | University of Massachusetts Worcester | Hybrid oligonucleotide phosphorothioates |
| 7432249, | Jun 06 1996 | ISIS Pharmaceuticals, Inc. | Oligoribonucleotides and ribonucleases for cleaving RNA |
| 7432250, | Jun 06 1996 | Ionis Pharmaceuticals, Inc | Oligoribonucleotides and ribonucleases for cleaving RNA |
| 7629321, | Jun 06 1996 | ISIS Pharmaceuticals, Inc. | Oligoribonucleotides and ribonucleases for cleaving RNA |
| 7695902, | Jun 06 1996 | ISIS Pharmaceuticals, Inc. | Oligoribonucleotides and ribonucleases for cleaving RNA |
| 7785782, | Dec 12 2002 | Novartis Vaccines and Diagnostics, Inc | Device and method for in-line blood testing using biochips |
| 7812149, | Jun 06 1996 | Isis Pharmaceuticals, Inc | 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations |
| 7884086, | Sep 08 2004 | Ionis Pharmaceuticals, Inc | Conjugates for use in hepatocyte free uptake assays |
| 8394947, | Mar 03 2004 | Ionis Pharmaceuticals, Inc | Positionally modified siRNA constructs |
| 8524680, | Feb 01 2002 | Applied Biosystems, LLC | High potency siRNAS for reducing the expression of target genes |
| 8569474, | Mar 08 2004 | Ionis Pharmaceuticals, Inc | Double stranded constructs comprising one or more short strands hybridized to a longer strand |
| 8604183, | Nov 05 2002 | Ionis Pharmaceuticals, Inc | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
| 8815821, | Feb 01 2002 | Life Technologies Corporation | Double-stranded oligonucleotides |
| 9096636, | Jun 06 1996 | Isis Pharmaceuticals, Inc | Chimeric oligomeric compounds and their use in gene modulation |
| 9592250, | Feb 01 2002 | Life Technologies Corporation | Double-stranded oligonucleotides |
| 9777275, | Feb 01 2002 | Life Technologies Corporation | Oligonucleotide compositions with enhanced efficiency |
| 9796978, | Feb 01 2002 | Life Technologies Corporation | Oligonucleotide compositions with enhanced efficiency |
| Patent | Priority | Assignee | Title |
| EP421376A1, |
| Executed on | Assignor | Assignee | Conveyance | Frame | Reel | Doc |
| Mar 18 1997 | University of Massachusetts Worcester | (assignment on the face of the patent) | / | |||
| Jun 26 1997 | GOODCHILD, JOHN | HYBRIDON, INC | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 008668 | /0511 | |
| Jan 07 2000 | GOODCHILD, JOHN | MASSACHUSETTS WORCESTER, UNIVERSITY OF | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 010542 | /0542 |
| Date | Maintenance Fee Events |
| Dec 11 2000 | ASPN: Payor Number Assigned. |
| Dec 11 2000 | RMPN: Payer Number De-assigned. |
| Jan 12 2004 | M2551: Payment of Maintenance Fee, 4th Yr, Small Entity. |
| Jan 21 2008 | REM: Maintenance Fee Reminder Mailed. |
| Jul 11 2008 | EXP: Patent Expired for Failure to Pay Maintenance Fees. |
| Date | Maintenance Schedule |
| Jul 11 2003 | 4 years fee payment window open |
| Jan 11 2004 | 6 months grace period start (w surcharge) |
| Jul 11 2004 | patent expiry (for year 4) |
| Jul 11 2006 | 2 years to revive unintentionally abandoned end. (for year 4) |
| Jul 11 2007 | 8 years fee payment window open |
| Jan 11 2008 | 6 months grace period start (w surcharge) |
| Jul 11 2008 | patent expiry (for year 8) |
| Jul 11 2010 | 2 years to revive unintentionally abandoned end. (for year 8) |
| Jul 11 2011 | 12 years fee payment window open |
| Jan 11 2012 | 6 months grace period start (w surcharge) |
| Jul 11 2012 | patent expiry (for year 12) |
| Jul 11 2014 | 2 years to revive unintentionally abandoned end. (for year 12) |